Coronavirus Update: Can IL-6 Drugs Cut Deaths? Kevzara Trials Start In Worst Hit Countries
Plus: J&J's Vaccine Could Be Ready By Early 2021
News from around the biopharma sector and its efforts to meet the challenges posed by the coronavirus pandemic.
You may also be interested in...
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.